EGFR and non-small cell lung carcinoma: Osimertinib, a third‐generation TKI, has been widely used in advanced NSCLC with mutations due to its superior therapeutic efficacy in inhibiting both EGFR‐TKI‐sensitizing and EGFR p.Thr790Met (T790M) resistance mutations.6